1. Monteiro, R, Azevedo, I (2010). Chronic inflammation in obesity and the metabolic syndrome. Mediators of Inflammation 2010: 289645.
Google Scholar | Crossref | Medline | ISI2. Van Greevenbroek, MM, Schalkwijk, CG, Stehouwer, CD (2013). Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. The Netherlands Journal of Medicine 71: 174–187.
Google Scholar | Medline3. Blüher, M (2019) Obesity: global epidemiology and pathogenesis. Nature reviews. Endocrinology 15: 288–298.
Google Scholar | Crossref | Medline4. Poirier, P, Giles, TD, Bray, GA, et al. (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 113: 898–918.
Google Scholar | Crossref | Medline | ISI5. Mathieu, P, Pibarot, P, Despres, J-P (2006) Metabolic syndrome: the danger signal in atherosclerosis. Vascular Health and Risk Management 2(3): 285–302.
Google Scholar | Crossref | Medline6. Karasawa, K., Harada, A., Satoh, N., et al. (2003) Plasma platelet activating factor-acetylhydrolase (PAF-AH). Progress in Lipid Research 42(2): 93–114.
Google Scholar | Crossref | Medline7. Tellis, CC, Moutzouri, E, Elisaf, M, et al. (2013) The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA 2 constantinos. Journal of Lipid Research 54(12): 3394–3402.
Google Scholar | Crossref | Medline8. Häkkinen, T, Luoma, JS, Hiltunen, MO, et al. (1999) Lipoprotein‐associated phospholipase A2, platelet‐activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 19: 2909–2917.
Google Scholar | Crossref | Medline | ISI9. Packard, CJ, O’Reilly, DSJ, Caslake, MJ, et al. (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. New England Journal of Medicine 343(16): 1148–1155.
Google Scholar | Crossref | Medline | ISI10. Ntzouvani, A, Giannopoulou, E, Fragopoulou, E, et al. (2019) Energy intake and plasma adiponectin as potential determinants of lipoprotein-associated phospholipase A2 activity: a cross-sectional study. Lipids 54: 629–640.
Google Scholar | Crossref | Medline11. Sertić, J, Skorić, B, Lovrić, J, et al. (2010) Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease? Acta medica Croatica: casopis Hravatske akademije medicinskih znanosti 64(4): 237–245.
Google Scholar | Medline12. Kurniawan, LB, Rampo, H, Soraya, GV, et al. (2021) Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 diabetes mellitus patients. Obesity Medicine 22: 100318.
Google Scholar | Crossref13. D, Bonnefont-Rousselot (2016) Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques. Annales Pharmaceutiques Francaises 74(3): 190–197.
Google Scholar | Crossref | Medline14. Liapikos, TA, Antonopoulou, S, Karabina, S-AP, et al. (1994) Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1212: 353–360.
Google Scholar | Crossref | Medline15. Laura, J, Warunee, K, Moore, JD, et al. (2018) Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids. Diabetologia 61(5): 1155–1166.
Google Scholar | Crossref | Medline16. Reddy, KJ, Singh, M, Bangit, JR, et al. (2009) The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review. Journal of Clinical Lipidology 3(2): 85–93.
Google Scholar | Crossref | Medline17. DiaDexus (2014) FDA clears test to help predict risk of coronary heart disease. December 18, 2014.
Google Scholar18. Weisell, RC (2002) Body mass index as an indicator of obesity. Asia Pacific Journal of Clinical Nutrition 11(suppl l): S681–S684.
Google Scholar | Crossref19. Yoo, E-G (2016) Waist-to-height ratio as a screening tool for obesity and cardiometabolic risk. Korean Journal of Pediatrics 59(11): 425–431.
Google Scholar | Crossref | Medline20. Salvi, P (2012) Pulse Waves, How Vascular Hemodynamics Affects Blood Pressure. 1st edition. Milan, Italy: Springer-Verlad Mailand, XII, 138.
Google Scholar21. Ryan, AS (2000) Insulin resistance with aging: effects of diet and exercise. Sports Medicine 30(5): 327–346.
Google Scholar | Crossref | Medline22. Gregson, J, Stirnadel-Farrant, HA, Doobaree, IU, et al. (2012) Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature. Atherosclerosis 225(1): 11–21.
Google Scholar | Crossref | Medline23. De Stefano, A, Mannucci, L, Tamburi, F, et al. (2019) Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. International Journal of Immunopathology and Pharmacology 33: 1–4.
Google Scholar | SAGE Journals24. Rana, JS, Arsenault, BJ, Despres, J-P, et al. (2011) Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. European Heart Journal 32(3): 336–344.
Google Scholar | Crossref | Medline25. Acevedo, M, Varleta, P, Kramer, V, et al. (2015) Comparison of lipoprotein-associated phospholipase A2 and high sensitive C-reactive protein as determinants of metabolic syndrome in subjects without coronary heart disease: In search of the best predictor. International Journal of Endocrinology 2015: 934681.
Google Scholar | Crossref | Medline26. Persson, M, Bo, H, et al. (2007) Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subject. Arteriosclerosis, Thrombosis, and Vascular Biology 27(6): 1411–1416.
Google Scholar | Crossref | Medline27. Noto, H, Chitkara, P, Raskin, P (2006) The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. Journal of Diabetes and its Complications 20: 343–348.
Google Scholar | Crossref | Medline28. Gong, H-p, Du, Y-m, Zhong, L-n, et al. (2011) Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids in Health and Disease 10: 13.
Google Scholar | Crossref | Medline | ISI29. Topbas, C, Swick, A, Razavi, M, et al. (2018) Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and activity assays. Clinical Chemistry 64(4): 697–704.
Google Scholar | Crossref | Medline30. Chu, N-F (2005) Prevalence of obesity in Taiwan. Obesity Reviews 6(4):271–274.
Google Scholar | Crossref | Medline31. Acevedo, M, Varleta, P, Kramer, V, et al. (2015) Comparison of lipoprotein-associated phospholipase A2 and high sensitive C-reactive protein as determinants of metabolic syndrome in subjects without coronary heart disease: in search of the best predictor. International Journal of Endocrinology 2015: 934681.
Google Scholar | Crossref | Medline32. Hui, DY (2012) Phospholipase A2 enzymes in metabolic and cardiovascular diseases. Current Opinion in Lipidology 23(3): 235–240.
Google Scholar | Crossref | Medline33. Feng, L-M, Feng, G-F, Chen, Y (2014) Evaluation of lipoprotein-associated phospholipase A2 in healthy chinese han adult serum. Lipids in Health and Disease 13: 6.
Google Scholar | Crossref | Medline34. Winkler, K, Winkelmann, BR, Scharnagl, H, et al. (2005) Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen risk and cardiovascular health study. Circulation 111(8): 980–987.
Google Scholar | Crossref | Medline35. Yoshimura, T, Ohshige, A, Maeda, T, et al. (1999) Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women. Maturitas 31(3): 249–253.
Google Scholar | Crossref | Medline36. Da Silva, IT, Timm, AdS, Damasceno, NR (2013) Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids in Health and Disease 12: 19.
Google Scholar | Crossref | Medline | ISI37. Seyfarth, J, Reinehr, T, Hoyer, A, et al. (2018) Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes. Journal of Inherited Metabolic Disease 41: 73–79.
Google Scholar | Crossref | Medline